6,140 reports of this reaction
2.6% of all WARFARIN reports
#4 most reported adverse reaction
FATIGUE is the #4 most commonly reported adverse reaction for WARFARIN, manufactured by Amneal Pharmaceuticals LLC. There are 6,140 FDA adverse event reports linking WARFARIN to FATIGUE. This represents approximately 2.6% of all 237,331 adverse event reports for this drug.
WARFARIN has an overall safety score of 92 out of 100. Patients taking WARFARIN who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for WARFARIN, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for WARFARIN:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 6,140 FDA reports for WARFARIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.6% of all adverse event reports for WARFARIN, making it a notable side effect.
If you experience fatigue while taking WARFARIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.